| Atorvastatin given prior to electrical cardioversion does not affect the recurrence of atrial fibrillation in patients with persistent atrial fibrillation who are on antiarrhythmic therapy. | |
| | |
MedLine Citation:
|
PMID: 21757938 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: In this study, our aim was to evaluate the effect of a higher dose of atorvastatin on the recurrence rate of atrial fibrillation (AF) after electrical cardioversion (EC) in addition to antiarrhythmic therapy. SUBJECTS AND METHODS: 48 patients with persistent AF were included in this study. The patients were randomized to an atorvastatin 40-mg treatment group and a control group. Atorvastatin was started 3 weeks before EC and was continued for 2 months after EC. EC was performed using biphasic shocks after 3 weeks of treatment with the orally administered anticoagulant warfarin. Lipid and inflammatory parameters (high-sensitivity C-reactive protein, white blood cell count and fibrinogen level) were evaluated at the baseline and before EC. The endpoint of this study was electrocardiographically confirmed recurrence of AF of >10 min. RESULTS: There were no significant differences in baseline characteristics and lipid and inflammatory marker levels between the treatment and control groups. Total cholesterol and low-density lipoprotein levels were significantly decreased in patients taking atorvastatin for 2 months compared with baseline values (174 ± 31 vs. 129 ± 25 mg/dl, p = 0.001, and 112 ± 23 vs. 62 ± 20 mg/dl, p = 0.001, respectively), while no significant change occurred in control patients (168 ± 26 vs. 182 ± 29 mg/dl, p = 0.07, and 99 ± 18 vs. 108 ± 26 mg/dl, p = 0.1, respectively). At the end of the 2-month follow-up period, 9 patients (20.5%) experienced AF recurrence, and there was no significant difference in AF recurrence rate between the treatment and control groups (26 vs. 13%; p = 0.2). CONCLUSION: Atorvastatin therapy prior to EC does not prevent the recurrence of arrhythmia in patients with persistent AF who are receiving antiarrhythmic therapy. |
| | |
Authors:
|
Kenan Demir; Ilknur Can; Fatih Koc; Mehmet Akif Vatankulu; Selim Ayhan; Hakan Akilli; Alpay Aribas; Yusuf Alihanoglu; Bulent Behlul Altunkeser |
Related Documents
:
|
21880458 - Total vs hemi-aortic arch transposition for hybrid aortic arch repair. 21057148 - Contractures of the upper extremities in spinal muscular atrophy type ii. descriptive c... 21762298 - Outcomes of contemporary management of gangrenous and non-gangrenous acute cholecystitis. 22033608 - One-stage anterolateral surgical treatment for lumbosacral segment tuberculosis. 19664508 - Incidence and treatment of postoperative stiffness following arthroscopic rotator cuff ... 17087998 - Comparison of bupivacaine and ropivacaine on postoperative pain after tonsillectomy in ... |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial Date: 2011-07-11 |
Journal Detail:
|
Title: Medical principles and practice : international journal of the Kuwait University, Health Science Centre Volume: 20 ISSN: 1423-0151 ISO Abbreviation: Med Princ Pract Publication Date: 2011 |
Date Detail:
|
Created Date: 2011-07-15 Completed Date: 2011-12-07 Revised Date: 2012-01-26 |
Medline Journal Info:
|
Nlm Unique ID: 8901334 Medline TA: Med Princ Pract Country: Switzerland |
Other Details:
|
Languages: eng Pagination: 464-9 Citation Subset: IM |
Copyright Information:
|
Copyright © 2011 S. Karger AG, Basel. |
Affiliation:
|
Department of Cardiology, School of Medicine, Selcuk University, Tokat, Turkey. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Analysis of Variance Anti-Arrhythmia Agents / administration & dosage*, therapeutic use Anticholesteremic Agents / administration & dosage*, therapeutic use Anticoagulants / therapeutic use Atrial Fibrillation / drug therapy, pathology, prevention & control* C-Reactive Protein Chronic Disease Electric Countershock / instrumentation, methods* Female Fibrinogen / analysis Health Status Indicators Heptanoic Acids / administration & dosage*, therapeutic use Humans Leukocyte Count Male Middle Aged Pyrroles / administration & dosage*, therapeutic use Recurrence / prevention & control Time Factors Warfarin / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Arrhythmia Agents; 0/Anticholesteremic Agents; 0/Anticoagulants; 0/Heptanoic Acids; 0/Pyrroles; 110862-48-1/atorvastatin; 81-81-2/Warfarin; 9001-32-5/Fibrinogen; 9007-41-4/C-Reactive Protein |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Impact of asymptomatic malaria on some hematological parameters in the iwo community in southwestern...
Next Document: Postoperative analgesia in impacted third molar surgery: the role of preoperative diclofenac sodium,...